CHF-6333
- Generic Name
- CHF-6333
- Drug Type
- Small Molecule
- Chemical Formula
- C28H31F3N6O6S
- CAS Number
- 1613621-54-7
- Unique Ingredient Identifier
- Q0656F336Y
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 45
- Registration Number
- NCT06166056
- Locations
- 🇬🇧
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, United Kingdom
🇬🇧NHS Lothian, Edinburgh, United Kingdom
🇬🇧The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds, United Kingdom
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
Phase 1
Completed
- Conditions
- Cystic FibrosisNon-Cystic Fibrosis Bronchiectasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 68
- Registration Number
- NCT04010799
- Locations
- 🇩🇪
IKF Institut für klinische Forschung Pneumologie, Frankfurt/Main, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath